

SECTOR: Specialty Pharmaceuticals

December 10, 2013

Reminder: Be sure to register for the Guggenheim Securities 2013 Boston Healthcare Day on Tuesday, December 17, by contacting your Guggenheim institutional sales representative. This event will consist of a full day of one-on-one private meetings with senior management from AZN, ALXN, INCY, MDCO, IPXL, LCI, ARIA, CADX, SGNT, ATRS, HZNP, PETX, MACK, ACRX, CEMP, SCMP, DRTX, TTPH, VSTM, BDSI, FPRX, DRRX, BOTA.

The USDA released its monthly WASDE (World Agriculture Supply and Demand Estimates) today. The report supports our belief that livestock expansion for poultry and swine will pick up in 2014 and cattle will pick up in 2015. This would be good for ZTS (BUY, \$31.75), as 64% of its revenues in 3Q13 came from livestock. The key data points that support our positive investment thesis are highlighted below.

- The projected season-average farm price for corn is projected \$0.10 cents lower (was \$4.10 to \$4.90 in November) at the
  midpoint with the range narrowed to \$4.05 to \$4.75 per bushel based on prices reported to date (down 31% to 41% YOY).
  Last year, the price of corn was \$6.90. With a record crop now estimated for Canada, additional quantities of Canadian corn
  are expected to find their way into the U.S. market.
- The U.S. season-average soybean price is projected up \$0.35 at both ends of the range (was \$11.15 to \$13.15 in November) to \$11.50 to \$13.50 per bushel (down 6% to 20% YOY). Last year, the price of soybean was \$14.40.
- The forecasts for total red meat and poultry production for both 2013 and 2014 are raised from November.

**Potential Stock Moving Catalysts.** 1) Operating margin expansion; 2) new product launches; 3) business development; 4) expansion into adjacent categories; 5) U.S. drought subsides



SECTOR: SPECIALTY PHARMACEUTICALS December 10, 2013

## ANALYST CERTIFICATION

By issuing this research report, each Guggenheim Securities, LLC ("Guggenheim Securities") research analyst whose name appears in this report hereby certifies that (i) all of the views expressed in this report accurately reflect the research analyst's personal views about any and all of the subject securities or issuers discussed herein and (ii) no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst.

## IMPORTANT DISCLOSURES

The research analyst(s) and research associate(s) have received compensation based upon various factors, including quality of research, investor client feedback, and Guggenheim Securities, LLC's overall revenues, which includes investment banking revenues.

Guggenheim Securities, LLC managed or co-managed a public offering of securities for Zoetis Inc. during the past 12 months.

Zoetis Inc. is or was during the 12-month period preceding the date of the distribution of this report a client of Guggenheim Securities. Guggenheim Securities, LLC Provided Zoetis Inc.investment banking services.

Guggenheim Securities, LLC or its affiliates expect(s) to receive or intend(s) to seek compensation for investment banking services from Zoetis Inc. in the next 3 months.

Please refer to this website for company-specific disclosures referenced in this report: <a href="https://guggenheimsecurities.bluematrix.com/sellside/Disclosures.action">https://guggenheimsecurities.bluematrix.com/sellside/Disclosures.action</a>. Disclosure information is also available from Compliance, 330 Madison Avenue, New York, NY 10017.



## RATING DEFINITIONS

BUY (B) - Describes stocks that we expect to provide a total return (price appreciation plus yield) of 15% or more within a 12-month period.

NEUTRAL (N) - Describes stocks that we expect to provide a total return (price appreciation plus yield) of plus 15% or minus 15% within a 12-month period.

SELL (S) - Describes stocks that we expect to provide a total negative return (price appreciation plus yield) of 15% or more within a 12-month period.

NR - The investment rating and price target have been temporarily suspended. Such suspensions are in compliance with applicable regulations and/or Guggenheim Securities, LLC policies.

CS - Coverage Suspended. Guggenheim Securities, LLC has suspended coverage of this company.

NC - Not covered. Guggenheim Securities, LLC does not cover this company.

**Restricted** - Describes issuers where, in conjunction with Guggenheim Securities, LLC engagement in certain transactions, company policy or applicable securities regulations prohibit certain types of communications, including investment recommendations.

**Monitor** - Describes stocks whose company fundamentals and financials are being monitored, and for which no financial projections or opinions on the investment merits of the company are provided.

Guggenheim Securities, LLC methodology for assigning ratings may include the following: market capitalization, maturity, growth/value, volatility and expected total return over the next 12 months. The price targets are based on several methodologies, which may include, but are not restricted to, analyses of market

Page 2



#### SECTOR: SPECIALTY PHARMACEUTICALS

December 10, 2013

risk, growth rate, revenue stream, discounted cash flow (DCF), EBITDA, EPS, cash flow (CF), free cash flow (FCF), EV/EBITDA, P/E, PE/growth, P/CF, P/FCF, premium (discount)/average group EV/EBITDA, premium (discount)/average group P/E, sum of the parts, net asset value, dividend returns, and return on equity (ROE) over the next 12 months.

## RATINGS DISTRIBUTIONS FOR GUGGENHEIM SECURITIES:

			IB Serv./ Past 12Mos.	
Rating Category	Count	Percent	Count	Percent
Buy	101	51.53%	16	15.84%
Neutral	94	47.96%	8	8.51%
Sell	1	0.51%	0	0.00%

## OTHER DISCLOSURES

This research is for our clients and prospective clients only. Other than disclosures relating to Guggenheim Securities and its affiliates, this research is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. We seek to update our research as appropriate, but various regulations may prevent us from doing so. Other than certain industry reports published on a periodic basis, the large majority of reports are published at irregular intervals as appropriate in the research analyst's judgment. Guggenheim Securities conducts a full-service, integrated investment banking and brokerage business, and one or more of its affiliates conduct an investment management business. Guggenheim Securities is a member of SIPC (<a href="http://www.sipc.org">http://www.sipc.org</a>). Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients and our employees trading for our own account that reflect opinions that are contrary to the opinions expressed in this research. Guggenheim Securities or certain of its affiliates conducts an investment management business, trades for its own account, and conducts an investment business, and may make investment decisions that are inconsistent with the recommendations or views expressed in this research.

We and our affiliates, officers, directors, and employees, excluding equity and credit analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives, if any, referred to in this research. We and our affiliates also may sell to or buy from customers on a principal basis the securities described herein. We and our affiliates also do business with, or that relates to, companies covered in Guggenheim Securities' research, and may have a position in the debt of the company or companies discussed herein.

This research is not an offer to sell or the solicitation of an offer to buy any security. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any advice or recommendation in this research is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of investments referred to in this research and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.

## TACTICAL TRADING IDEA DISCLAIMER

Guggenheim Securities, LLC produces "Tactical Trade Ideas" that identify short-term, catalyst-driven trading opportunities impacting companies within the Firm's coverage universe. Tactical Trade Ideas may exist on companies in this report and may be contrary to the analyst's published rating.

Copyright © 2013 by Guggenheim Securities, LLC, ("Guggenheim") a FINRA registered broker-dealer. All rights reserved. The contents of this report are based upon information or are obtained from sources that Guggenheim generally considers reliable, but Guggenheim makes no representations or warranties with respect to their accuracy, completeness, timeliness, suitability or otherwise, and assumes no responsibility to update them for subsequent events or knowledge. Guggenheim is not responsible for your use of this information.

### **Contact Information**

## NEW YORK SALES & TRADING DESK

212 292 4700

### **EQUITY TRADING DESK**

212 292 4701

#### **MEDIA INQUIRIES**

310 367 6567

#### **EMAIL**

general@guggenheimcm.com

#### Locations

#### **NEW YORK**

ROSTON

330 Madison Avenue New York, NY 10017

## WASHINGTON, DC

1055 Thomas Jefferson Street, NW Suite 450

500 Boylston Street, 13th Floor

Washington, DC 20007

Boston, MA 02116

#### **DALLAS**

Suite 4005

LOS ANGELES

601 South Figueroa Street

Los Angeles, CA 90017

1717 McKinney Avenue Suite 870 Dallas, TX 75202

SAN FRANCISCO 50 California Street San Francisco, CA 94111

#### NASHVILLE

104 Woodmont Blvd Suite 203 Nashville, TN 37205

### **HERNANDO**

1288 Byhalia Road Suite 2

Hernando, MS 38632

## Guggenheim Equity Research

#### **AUTOMOTIVE**

### Matthew Stover, Analyst

matthew.stover@guggenheimpartners.com 617 859 4605

#### Brendon Mason, Associate

brendon.mason@guggenheimpartners.com 617 859 4624

## ENERGY: EXPLORATION & PRODUCTION Rob Cordray, Analyst

robert.cordray@guggenheimpartners.com 972 638 5509

#### Steven Hader, Associate

steven.hader@guggenheimpartners.com 972 638 5507

#### **ENERGY: OIL SERVICES & EQUIPMENT**

## Darren Gacicia, Analyst

darren.gacicia@guggenheimpartners.com 212 293 3054

### Michael Gunther, Associate

michael.gunther@guggenheimpartners.com 212 518 9782

#### Michael LaMotte, Analyst

michael.lamotte@guggenheimpartners.com 972 638 5502

## Wilson Waggoner, Associate

wilson.waggoner@guggenheimpartners.com 972 638 5506

## FINANCIAL SERVICES: LARGE-CAP BANKS

### Marty Mosby, Analyst

marty.mosby@guggenheimpartners.com 662 469 9595

#### Mason Mosby, Associate

mason.mosby @guggenheimpartners.com 662 469 9194

# FINANCIAL SERVICES: REGIONAL & COMMUNITY BANKS, CARD NETWORKS

## Taylor Brodarick, Analyst

taylor.brodarick@guggenheimpartners.com 615 208 1222

## **David Darst, Analyst**

david.darst@guggenheimpartners.com 615 208 1224

## Rahul Agarwal, Associate

rahul.agarwal@guggenheimpartners.com 615 208 1221

## FINANCIAL SERVICES: INSURANCE Bijan Moazami, Analyst

bijan.moazami@guggenheimpartners.com 202 747 9466

## HEALTHCARE: BIOTECH Bret Holley, Analyst

bret.holley@guggenheimpartners.com 212 293 2820

#### Daniel Chung, Associate

daniel.chung@guggenheimpartners.com 212 518 9771

# HEALTHCARE: PHARMACEUTICALS Louise Chen, Analyst

louise.chen@guggenheimpartners.com 212 381 4195

#### Swati Kumar, Associate

swati.kumar@guggenheimpartners.com 212 918 8754

# RETAIL & CONSUMER John Heinbockel, Analyst

john.heinbockel@guggenheimpartners.com 212 381 4135

#### Steven Forbes, Associate

steven.forbes@guggenheimpartners.com 212 381 4188

## TMT: CABLE & SATELLITE TV

## Sabina Nyckowski, Analyst

sabina.nyckowski@guggenheimpartners.com 212 292 4778

# TMT: MEDIA & ENTERTAINMENT Michael Morris, Analyst

michael.morris@guggenheimpartners.com 212 381 4162

#### Curry Baker, Associate

curry.baker@guggenheimpartners.com